Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients

Purpose of reviewThe aim of this review was to detail the current therapies and treatments for chronic hepatitis C virus in coinfected patients, focusing on HCV antiviral agents currently used in practice today or scheduled to enter the open market soon. Recent findingsSeveral direct-acting antiviral (DAA) combinations show high sustained virologic response (SVR) rates in HIV/HCV-coinfected patients, which are often close to those observed in HCV-monoinfected patients. Most recommendations regarding treatment stem from trials with coinfected patients. However, data are lacking for some aspects of HCV-treatment in coinfection, so extrapolations must be made from data obtained predominately from monoinfected patients. SummaryHIV/HCV-coinfected patients, who, not too long ago, had inferior outcomes in capturing SVR, now enjoy similar fates as the monoinfected patients. They should thus be prioritized for treatment, since HCV and liver disease have become major causes of morbidity and mortality in this population. However, potential drug–drug interactions between antiretroviral agents and DAAs have to be systematically anticipated before initiating HCV therapy.

[1]  T. Asselah,et al.  Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial , 2015, The Lancet.

[2]  D. Samuel,et al.  P0837 : Efficacy of sofosbuvir and daclatasvir in HIV/HCV co-infected patients with advanced fibrosis , 2015 .

[3]  T. Pilot‐Matias,et al.  Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. , 2015, JAMA.

[4]  Brad J. Wood,et al.  Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. , 2015, JAMA.

[5]  J. Rockstroh,et al.  Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study , 2015, The Lancet.

[6]  P. Thuluvath,et al.  All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study , 2015, Hepatology.

[7]  H. Dvory‐Sobol,et al.  Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis , 2015, Hepatology.

[8]  D. Neau,et al.  Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Brian L. Pearlman,et al.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study , 2014, The Lancet.

[10]  D. Dieterich,et al.  Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  K. Mounzer,et al.  Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. , 2014, JAMA.

[12]  Riina Salupere,et al.  Sofosbuvir and ribavirin in HCV genotypes 2 and 3. , 2014, The New England journal of medicine.

[13]  Thomas Berg,et al.  ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. , 2014, The New England journal of medicine.

[14]  R. Marinho,et al.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. , 2014, The New England journal of medicine.

[15]  Stefan Zeuzem,et al.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[16]  Robert Herring,et al.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[17]  Eoin Coakley,et al.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[18]  Sanjeev Arora,et al.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[19]  C. Stedman,et al.  O6 SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCE , 2014 .

[20]  Richard A. Stanton,et al.  Approaches to hepatitis C treatment and cure using NS5A inhibitors , 2014, Infection and Drug Resistance.

[21]  S. Khoo,et al.  Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection , 2014, Current opinion in infectious diseases.

[22]  A. Lok,et al.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.

[23]  R. Bertz,et al.  Assessment of Pharmacokinetic Interactions of the HCV Ns5A Replication Complex Inhibitor Daclatasvir with Antiretroviral Agents: Ritonavir-Boosted Atazanavir, Efavirenz and Tenofovir , 2013, Antiviral therapy.

[24]  H. Mo,et al.  Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885 , 2013, Antimicrobial Agents and Chemotherapy.

[25]  V. Soriano,et al.  Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV , 2013, Annals of Internal Medicine.

[26]  J. Mallolas,et al.  Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. , 2013, The Lancet. Infectious diseases.

[27]  Richard D Moore,et al.  Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults , 2007, AIDS.

[28]  Giorgio Palù,et al.  Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. , 2005, Journal of hepatology.

[29]  F. Carrat,et al.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. , 2004, JAMA.

[30]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[31]  R. Chung,et al.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[33]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[34]  M. Saag.  Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1 , 2016 .

[35]  Stefan Zeuzem,et al.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.